Health & Fitness
Fri, October 29, 2010Thu, October 28, 2010Wed, October 27, 2010Tue, October 26, 2010Mon, October 25, 2010Sun, October 24, 2010Sat, October 23, 2010Fri, October 22, 2010Thu, October 21, 2010Wed, October 20, 2010Tue, October 19, 2010Mon, October 18, 2010Sun, October 17, 2010Sat, October 16, 2010Fri, October 15, 2010Thu, October 14, 2010Wed, October 13, 2010Tue, October 12, 2010Mon, October 11, 2010Celldex Therapeutics to Present at Inaugural Cancer Immunotherapy Conference
Published in Health and Fitness on Wednesday, October 20th 2010 at 12:35 GMT by Market Wire
NEEDHAM, Mass.--([ BUSINESS WIRE ])--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the Company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place on October 21, 2010, at the New York Academy of Medicine in New York.
Thomas Davis, M.D., Senior Vice President and Chief Medical Officer, will provide an overview of the Companya™s Precision Targeted Immunotherapy Platform. Dr. Davis is scheduled to present at 1:45 pm EDT. Additionally, Tibor Keler, Ph.D., Senior Vice President and Chief Scientific Officer, will participate in a panel discussion titled aAutologous versus Allogeneic Immunotherapya at 2:45 pm EDT.
There will be a corresponding live webcast of the conference, which can be accessed by visiting [ http://www.mdbpartners.com/vaccine ].
Hosted by MD Becker Partners and BioBusiness.TV, the Cancer Immunotherapy: A Long-Awaited Reality conference includes keynote speakers, panelist and plenary sessions, company presentations, and intimate networking opportunities to meet the needs of all attendees. Pre-registration is required and attendance is limited to 150 individuals; no walk-ins. To register, or to obtain more information, please visit [ http://www.mdbpartners.com/vaccine ] or contact MD Becker Partners directly at [ info@mdbpartners.com ].
About Celldex Therapeutics, Inc.
Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. For more information, please visit [ http://www.celldextherapeutics.com ].
About MD Becker Partners
MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. The firm also works with venture capitalists, institutional investors, and others that provide capital to these companies. As a strategic advisor and partner, MD Becker Partners provides a full range of services to help its clients increase visibility, unlock stakeholder value, and access resources to grow their business. To accomplish this, the firm integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information visit [ http://www.mdbpartners.com ].
About BioBusiness.TV
BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. The company creates video-based, industry focused business news and analysis programs. BioBusiness.TV produces and syndicates videos ranging from news and stock picks, to equity analyst insights, as well as C-level executive interviews on strategy, management, policy, marketing, science, and more. BioBusiness.TVa™s latest Original Series, aThe Stem Cell Review,a is a 10-part TV program on the science, medical applications, and business of stem cells, which provides a clear and concise understanding of the state of stem cells today, with the additional depth and expertise you would come to expect from the most renowned authorities in the field. For more information, visit [ http://www.biobusiness.tv ].
